StockData
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. (ORKA) stock

ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$96.32−2.92 (-2.94%)

Close on Nov 17, 2026Market cap $6.38BP/E –Yield –

Oruka Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Oruka Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$100.92M. For fiscal 2025 it was -$88.21M. The highest annual figure on record is -$4.08M in fiscal 2012.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$88.21M–
FY2023Dec 31, 2023-$5.01M–
FY2022Dec 31, 2022-$10.91M–
FY2021Dec 31, 2021-$18.76M–
FY2020Dec 31, 2020-$7.73M–
FY2019Dec 31, 2019-$4.80M–
FY2018Dec 31, 2018-$8.24M–
FY2017Dec 31, 2017-$17.47M–
FY2016Dec 31, 2016-$14.99M–
FY2015Dec 31, 2015-$10.53M–
FY2014Dec 31, 2014-$9.41M–
FY2013Dec 31, 2013-$5.29M–
FY2012Dec 31, 2012-$4.08M–
FY2011Dec 31, 2011-$6.96M–
FY2010Dec 31, 2010-$8.32M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$33.15M–
Q1 FY2026Mar 31, 2026-$23.58M–
Q4 FY2025Dec 31, 2025-$22.59M–
Q3 FY2025Sep 30, 2025-$21.60M–
Q2 FY2025Jun 30, 2025-$23.15M–
Q1 FY2025Mar 31, 2025-$20.87M–
Q2 FY2024Jun 30, 2024-$2.63M–
Q1 FY2024Mar 31, 2024-$1.53M–
Q4 FY2023Dec 31, 2023-$1.06M–
Q3 FY2023Sep 30, 2023-$1.67M–
Q2 FY2023Jun 30, 2023-$694.00K–
Q1 FY2023Mar 31, 2023-$1.60M–
Q4 FY2022Dec 31, 2022-$1.49M–
Q3 FY2022Sep 30, 2022-$2.50M–
Q2 FY2022Jun 30, 2022-$2.62M–
Q1 FY2022Mar 31, 2022-$4.30M–
Q4 FY2021Dec 31, 2021-$4.95M–
Q3 FY2021Sep 30, 2021-$4.87M–
Q2 FY2021Jun 30, 2021-$3.72M–
Q1 FY2021Mar 31, 2021-$5.23M–
Q4 FY2020Dec 31, 2020-$3.00M–
Q1 FY2020Mar 31, 2020-$1.69M–
Q4 FY2019Dec 31, 2019-$1.16M–
Q3 FY2019Sep 30, 2019-$887.00K–
Q2 FY2019Jun 30, 2019-$1.19M–
Q1 FY2019Mar 31, 2019-$1.57M–
Q4 FY2018Dec 31, 2018-$1.34M–
Q3 FY2018Sep 30, 2018-$1.58M–
Q2 FY2018Jun 30, 2018-$2.25M–
Q1 FY2018Mar 31, 2018-$3.07M–
Q4 FY2017Dec 31, 2017-$4.20M–
Q3 FY2017Sep 30, 2017-$3.97M–
Q2 FY2017Jun 30, 2017-$4.96M–
Q1 FY2017Mar 31, 2017-$4.34M–
Q4 FY2016Dec 31, 2016-$3.84M–
Q3 FY2016Sep 30, 2016-$3.74M–
Q2 FY2016Jun 30, 2016-$3.53M–

More Oruka Therapeutics figures

See a number that looks wrong?